2 research outputs found
Uptake of the first to fifth doses of coronavirus disease 2019 vaccine in individuals with chronic lymphocytic leukaemia: A nationwide cohort study in Sweden
No full textAbstract Objectives Patients with chronic lymphocytic leukaemia (CLL) have an increased risk of severe coronavirus disease 2019 (COVID‐19) as well as impaired responses to COVID‐19 vaccination, which may be overcome by repeated booster vaccinations. Our objective was to explore the uptake of the COVID‐19 vaccine in this population since records of this are scarce. Methods In this nationwide cohort study, we used multiple population‐based health and sociodemographic registries to study COVID‐19 vaccine uptake in individuals with CLL in Sweden, from 27 December 2020 to 28 February 2023. Results A total of 6304 individuals were included. The cumulative incidence (95% confidence interval) at the end of the study period was 95%, 94%, 88%, 78% and 56% for the first, second, third, fourth and fifth doses, respectively. The uptake was significantly higher compared with the age‐standardized nationwide uptake. However, there were large disparities, especially for the fourth and fifth doses, across different age groups, birth regions, and income quartiles. These differences were especially pronounced in intersectional analyses, where individuals born abroad in the lowest income quartile had a vaccine uptake of only 49% and 24% for the fourth and fifth doses, respectively. Conclusions Even though uptake was generally high in individuals with CLL, it seems to be declining from dose three and onwards, and there are significant sociodemographic disparities in vaccine uptake
Sociodemographic factors influencing SARS-CoV-2 vaccination uptake in people with and without HIV : Insights from a Swedish Nationwide cohort
No full textBACKGROUND: There is limited data regarding SARS-CoV-2 vaccine uptake in people with HIV (PWH) compared to people without HIV (PWoH).METHODS: Swedish nationwide study of individuals born 1930-2003, assessing SARS-CoV-2 vaccine uptake of 1-5 doses by HIV-status from first SARS-CoV-2 vaccination (2020-12-27) until 2023-02-23. PWH were categorized by prioritization: clinically vulnerable (CD4+ T-cells 200copies/mL), and not prioritized (non-vulnerable PWH). Relative risks (adjRR) for doses 1-5 were estimated using modified Poisson regression, adjusted for sociodemographics, SARS-CoV-2 infections, and comorbidities.RESULTS: 7233 non-vulnerable PWH, 435 clinically vulnerable PWH, and 8,168,340 PWoH were included. While unadjusted 3-dose uptake was lower in both PWH groups compared to PWoH, adjusted analysis showed higher uptake in non-vulnerable PWH (adjRR1.17, 95 % CI 1.15-1.19), with similar trends in clinically vulnerable. An interaction between country of birth and HIV-status was identified (p < 0.001). Migrants with HIV had higher 3-dose uptake vs. migrants without HIV, but were less likely vaccinated than Swedish-born with HIV. Among people ≥65 years old, PWH were less likely to receive 3 or more doses compared to PWoH ≥65 years (dose 5: adjRR 0.90, 95 % CI 0.85-0.96).CONCLUSIONS: We found lower vaccination uptake in migrants, irrespective of HIV-status, consistent with previous studies. Most concerningly we identified a lower vaccine uptake among people with HIV who were 65 years or older. This nationwide study highlights the need for targeted vaccination strategies and interventions that address both HIV-status and demographic factors
